GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price looking cheap to me?

Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post GSK shares leap 5% as results top forecasts and guidance is upgraded! Can ...

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Over the past year, the GSK (LSE: GSK) share price has lagged behind the FTSE 100, falling 14% versus the Footsie’s gain of ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run ...

UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...